-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Suzhou, Shanghai, China and Palo Alto, California, USA November 4, 2021/PRNewswire/ - Genxi Biotech Group (NASDAQ: GRCL; referred to as "Genxi Bio") is committed to A global clinical-stage biopharmaceutical company that develops efficient and economical cell therapy for cancer treatment today announced that it will announce its allo-chimeric antigen receptor in the form of an electronic poster during the 63rd American Society of Hematology (ASH) Annual Meeting ( CAR) T cell therapy candidate product GC502, preclinical research data for the treatment of B cell malignant tumors
GC502 is a CD19/CD7 dual-targeted, ready-to-use allogeneic CAR-T cell monotherapy developed based on Genxi's proprietary TruUCAR technology platform for the treatment of B-cell malignancies
TruUCAR is a proprietary technology platform created by Genxi Bio to develop a series of high-quality allogeneic CAR-T cell therapies
Dr.
Dr.
The details of the e-poster report are as follows:
The 63rd ASH Annual Conference and Exhibition in 2021
Abstract 148500: Preclinical research results of allogeneic ready-to-use CD19/CD7 dual-targeted CAR-T cell therapy (GC502) in the treatment of B-cell malignancies
Abstract release time: 9:00 am, November 4, 2021
Title of Report Session: Cellular Immunotherapy: Basic Research and Translational Medicine
Poster display time: 5:30-7:30 pm on December 11, 2021
About GC502
GC502 is a CD19/CD7 dual-targeting ready-to-use allogeneic CAR-T therapy candidate product developed based on the TruUCAR platform
About Acute B Lymphocytic Leukemia (B-ALL) and Acute Non-Hodgkin Lymphoma (B-NHL)
Acute lymphocytic leukemia (ALL) is a malignant hematological tumor characterized by the abnormal proliferation of immature lymphocytes in the bone marrow.
Non-Hodgkin’s Lymphoma (NHL) is a type of hematological malignancy that originates in lymph nodes and other lymphoid tissues, and is commonly found in B cells (B-NHL)
About TruUCAR
TruUCAR is a technology platform of Genxi Biotech with intellectual property rights.
About Genxi Bio
Genxi Biotechnology Group (referred to as "Genxi Bio") is a global clinical-stage biopharmaceutical company dedicated to the discovery and development of breakthrough cell therapies
Cautionary statement regarding forward-looking statements
The statements in this press release regarding future expectations, plans, prospects, and other non-historical facts may include "forward-looking statements" as defined under the Private Securities Litigation Reform Act of 1995
[1] Data source: Clarivate | DRG: Acute Lymphoblastic Leukemia-Epidemiology
[2] Data source: Clarivate | DRG: Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia-Epidemiology
Source: Genxi Bio
